List of Hemangeol drug patents

Hemangeol is owned by Pierre Fabre Derma.

Hemangeol contains Propranolol Hydrochloride.

Hemangeol has a total of 2 drug patents out of which 0 drug patents have expired.

Hemangeol was authorised for market use on 14 March, 2014.

Hemangeol is available in solution;oral dosage forms.

Hemangeol can be used as method to treat infantile hemangioma, method to treat hemangioma..

The generics of Hemangeol are possible to be released after 16 October, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338489 PIERRE FABRE DERMA Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Oct, 2028

(5 years from now)

US8987262 PIERRE FABRE DERMA Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Oct, 2028

(5 years from now)

Drugs and Companies using PROPRANOLOL HYDROCHLORIDE ingredient

Market Authorisation Date: 14 March, 2014

Treatment: Method to treat hemangioma.; Method to treat infantile hemangioma

Dosage: SOLUTION;ORAL

How can I launch a generic of HEMANGEOL before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in